Women's Health Global Market Report 2024

The global women's health market has grown steadily in recent years. It will grow from $41.22 billion in 2023 to $43.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be attributed to several factors, including advancements in reproductive medicine, initiatives focused on awareness and education, empowerment and advocacy movements, advances in prenatal and postnatal care, and the development of hormone replacement therapies.

The global women's health market is expected to see strong growth in the next few years. It will grow to $53.69 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The anticipated growth in the forecast period can be attributed to the integration of precision medicine in gynecology, an increase in female-focused clinical trials, the widespread adoption of non-invasive prenatal testing, expanded access to fertility treatments, and a growing emphasis on mental health in women's healthcare. Key trends expected during the forecast period include the emergence of digital health solutions, the popularity of fertility tracking and reproductive health innovations, the development of non-hormonal contraceptive options, advancements in maternal health and pregnancy monitoring, innovations in women's health diagnostics, and the integration of artificial intelligence (AI) in the field.

The escalating prevalence of women-centric diseases stands as a significant driver propelling the growth trajectory of the women's health market. A surge in conditions such as anemia, osteoporosis, breast cancer, menopause, and others, attributed to diverse risk factors like family history, advancing age, early onset of menstruation or menopause post-55 years, obesity, among others, is fueling the demand for women's health products and services. These offerings cater to treating these diseases while prioritizing the overall health and wellness of women. For example, the American Cancer Society's report published in January 2023 highlighted cervical cancer's historical status as a leading cause of cancer-related deaths among American women. An estimated 13,960 new cases of invasive cervical cancer are projected to be diagnosed in the USA in 2023, with approximately 4,310 anticipated fatalities. Hence, the escalating incidence of women-centric diseases is steering the expansion of the women's health market.

An upsurge in the aging populace emerges as a significant catalyst propelling the advancement of the women's health market. The demographic shift towards an aging population, characterized by a burgeoning proportion of individuals aged 65 and above, necessitates an increased focus on women's health needs. Women within this demographic encounter a higher prevalence of diseases such as osteoporosis, breast cancer, and menopause-related issues. This demographic shift underscores the augmented demand for specialized women's health services and products. It accentuates the significance of preventive measures, screenings, and tailored healthcare interventions aimed at preserving the well-being and enhancing the quality of life for older women. Notably, the World Health Organization's October 2022 report predicts that by 2030, 1 in 6 individuals globally will be aged 60 years or older, with the population of people aged 60 years and older anticipated to double by 2050, reaching 2.1 billion. Thus, the burgeoning aging population significantly propels the women’s health market.

Innovations in women's health stand out as a prominent trend shaping the women's health market landscape. Leading companies in this sector are actively pursuing novel product developments to fortify their market presence. For instance, in November 2021, FemTec Health, a US-based startup specializing in women's health and beauty through technology and data-driven personalized care, introduced a pioneering data analytics platform named BiomeAI. This innovative platform utilizes genetic, consumer, microbiome, and biometric data to customize healthcare interventions for women. The BiomeAI engine harnesses deep machine learning and AI to translate this diverse data into tailored holistic healthcare strategies personalized for every individual woman.

Major players in the women’s health market are integrating innovative technologies like Transcutaneous Electrical Nerve Stimulation (TENS) to solidify their position. TENS is a non-invasive therapeutic technique involving a battery-operated device that emits low-voltage electrical currents through electrode pads placed on specific body areas. This technology, exemplified by Myoovi's September 2023 launch in the UK, offers relief for painful menstruation cramps. By generating electrical signals, TENS interferes with and obstructs pain signals attempting to reach the brain, thereby minimizing pain. This drug-free alternative helps women manage the discomfort associated with menstrual cramps, offering a promising solution.

A notable strategic acquisitions, such as Partners Group's acquisition of Axia Women's Health in May 2021, play a pivotal role in shaping the women's health market. Partners Group, a global private equity firm based in Switzerland, expanded its portfolio in North American healthcare businesses through this acquisition. Axia Women's Health, a US-based women's healthcare services firm, operates within the women's health market, consolidating its offerings and expertise within the domain. This strategic move further solidifies the diverse landscape and comprehensive services available within the women's healthcare sector.

Major companies operating in the women's health market report are AbbVie Inc., Bayer AG, Merck & Co Inc., Pfizer Inc., Agile Therapeutics, Amgen Inc., Apothecus Pharmaceutical Corporation, Blairex Laboratories Inc., Novartis AG, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Lupin Pharmaceuticals Inc., Johnson & Johnson Services Inc., Allergan PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Siemens AG, Hologic Inc., Celmatix Inc., HERA Biotech Inc., Juno Bio Inc., Maven Clinic Inc., MobileODT Ltd., Mylan N.V., ObsEva SA, Oviva Therapeutics Inc., Samphire Neuro Inc., Scailyte AG, Syrona Health AG

North America was the largest region in the women's health market in 2023. Asia-Pacific is expected to be the fastest-growing region in the women's health market report during the forecast period. The regions covered in the women's health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the women's health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of products related to women's health include devices, drugs, and pharmaceutical pipelines. Women's health devices are instrumental in treating medical conditions specific to women. This includes individuals aged 50 years and older, who may undergo hormonal treatment, non-hormonal treatment, and surgeries for a range of applications. These applications span postmenopausal osteoporosis, hormonal infertility, endometriosis, uterine fibroids, contraceptives, menopause, and polycystic ovary syndrome (PCOS). These women's health products are made available through various distribution channels, including hospitals, retail stores, and online pharmacies.

This report provides women’s health market statistics, including women’s health industry global market size, regional shares, competitors with a women’s health market share, detailed women’s health market segments, market trends and opportunities, and any further data you may need to thrive in the women’s health industry. This women’s health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The women's health market consists of revenues earned by entities by providing hormone therapy, birth control treatment, and other related services. The market value includes the value of related goods sold by the service provider or included within the service offering. The women's health market also includes sales of contraceptive devices and pharmaceuticals, densitometry, breast implants, obstetrics or gynecology biopsy, imaging devices, and drugs such as Xgeva, Evista, Mirena, Zometa, Reclast, and Class, among others, that are used in providing women's health services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.